An analysis of the cancer clinical trials for medicare beneficiaries

However, HCFA does have a legitimate interest in assuring that trials meet currently accepted standards for scientific merit and protection of research participants.

Physicians are highly educated and work extremely hard for their living. Trials produce information of value to future patients, and frequently benefit the people enrolled in them. Redirecting any ongoing effort will be difficult for reasons that are well understood.

Indeed, avoiding the cost of secondary insurance is an important reason why many seniors choose MA plans in the first place. First, the recommended reimbursement policy is designed to limit payments for an individual to roughly the cost of "standard care" for which he or she would be eligible if not enrolled in the trial.

Its designers claim that it will be functioning, at least in part, by early Such guidance would promote nationally uniform administration and minimize uncertainty for providers and patients about what will and will not be reimbursed.

In contrast, the introduction of new procedures is not governed by any regulatory authority. No new reimbursement policy is needed for routine care in trials of most investigational medical devices.

This definition does not mean, however, that any treatment simply called a "clinical trial" would qualify for reimbursement. However, a loophole in the regulations governing Medicare Advantage MA plans has created a disparity in the way that clinical trial services are covered for MA enrollees.

The result was an Executive Memorandum issued in June of that year that authorized Medicare payment for routine patient care costs associated with clinical trial participation, as well as for related medical complications. Fiscal intermediaries and carriers audit these interpretations by providers in clinical trials, as they now audit bills from providers for care outside of clinical trials.

Claims should be submitted in the same way they are for treatment outside of trials. Nonetheless, this provision is an essential component of the overall recommendation.

Between andthe number of individuals in MA plans rose from 5. In addition, the recommendations apply to all clinical trials involving any type of intervention in any aspect of health care and for any illness, for care that would be eligible for Medicare reimbursement outside of trials.

Full implementation will require additional thought when HCFA adopts a clinical trial reimbursement policy, but the committee urges that the new policy not create obstacles to clinical trial enrollment for beneficiaries in managed care.

The committee recommends a broad definition of clinical trials—including all phases and legitimate designs and all sources of sponsorship government, industry, or other —all of which should be equally eligible for reimbursement. Others will be cost reducing.

Medicare Advantage The Medicare Advantage MA program enables Medicare beneficiaries to choose health care coverage through private health plans rather than the traditional fee-for-service model. Unlike the basic recommendation regarding routine patient care costs, which applies to all clinical trials, this recommendation would limit reimbursement to randomized trials the equivalent of "phase 3" trials for drugs and devices.

If Medicare or trial sponsors fail to cover clinical care costs, patients should not be billed for those costs above what they would pay if they were not in a trial. This impression is apparent from the nature of legislation introduced in Congress to assure reimbursement for routine patient care costs, from statements of HCFA officials, and from remarks of providers.

Thus, investigators who enroll more patients in clinical trials gain more experience and are more likely to be confident using a new treatment in their practice once it is approved. Advice or an interpretation could, of course, be requested of HCFA at any time.

CMS has never adjusted the MA capitation rates to account for any costs related to the clinical trials coverage requirement.

Conversely, as with category A devices, Medicare should not pay routinely for procedures that are considered "experimental," although HCFA may and should choose to do so in specific trials.

The committee recommends limiting reimbursement to trials that have been reviewed and accepted by all relevant institutional review boards IRBs.

Greater uniformity would, in turn, decrease the uncertainty about reimbursement when providers and patients embark on a clinical trial.

It also would apply to routine care in trials of new versus standard drugs.

Medicare Advantage: Reforms Needed to Ensure Access to Clinical Trials

The committee is recommending explicit policy to legitimize reimbursement for much—though not all—of the care rendered to participants in clinical trials. Yes, it appears that higher payments are associated with higher prescription rates for some of the drugs in the study.

Reimbursement claims should bear an identification number assigned by the registry. This principle applies to payments for physicians and other providers, routine laboratory and other diagnostic tests, and any other services that comprise routine care for a given patient.

The rationale for extending coverage is straightforward. The committee believes this limitation is appropriate in order to avoid providing reimbursement for uncontrolled experimentation by practitioners.The objective of this study was to determine the extent to which clinical trials relied on by the CMS are applicable to Medicare beneficiaries.

Methods We performed a meta-analysis of data on 40 individuals from all trials included in the technology assessments for the 6 cardiovascular disease meetings of the CMS advisory panel and. Addressing Disparities in Cancer Care for Latino Medicare Beneficiaries The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Listing a study does not mean it has been evaluated by the U.S. Federal Government. Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer Clinical trials have not demonstrated that adjuvant chemotherapy improves survival for patients with resected stage II colon cancer.

improves overall survival. The most informative source of data comes from the International Multicentre Pooled Analysis. Medicare will help pay for some of your costs if you join a covered clinical research study. Medicare pays routine costs for items and services, including: National Cancer Institute's (NCI) Clinical Trials website; Return to search results.

Find someone to talk to. Medicare Coverage ~ Clinical Trials • items and services provided solely to satisfy data collection and analysis needs providers directly on a fee for service basis for covered clinical trial services for beneficiaries enrolled in M+C plans. Title: Medicare Coverage ~.

The University of Pittsburgh Cancer Institute study concluded that because of the significant personal expense necessitated by the CMS requirement to return to FFS Medicare, the disparity between eligibility of Medicare beneficiaries for clinical trials and clinical trial representation is likely related.

3 “Under-representation affects our.

An analysis of the cancer clinical trials for medicare beneficiaries
Rated 5/5 based on 62 review